Lumryz Gains Ground in Narcolepsy Treatment, Reports Avadel
Avadel Pharmaceuticals shared updates on the performance and reception of its new narcolepsy medication, Lumryz.
Source: sleepreviewmag.com
Greg Divis News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Greg Divis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Greg Divis Today - Breaking & Trending Today
Avadel Pharmaceuticals Announces Strong LUMRYZ Launch Performance and Provides Preliminary Fourth Quarter and Full Year 2023 Financial Highlights
08.01.2024 - - Approximately $19 million and $28 million of net revenue from sales of LUMRYZ estimated for the fourth quarter and full year 2023, respectively - - Generated continued robust demand for LUMRYZ with greater than 1,900 patients enrolled in ... Seite 1
Source: wallstreet-online.de
Avadel Pursues Pediatric Indication for Narcolepsy Drug Lumryz
Avadel Pharmaceuticals has submitted an sNDA to the FDA for Lumryz for treatment of cataplexy or EDS in the pediatric narcolepsy population.
Source: sleepreviewmag.com
Avadel Pharmaceuticals plc (NASDAQ:AVDL) Q3 2023 Earnings Call Transcript
Operator: Greetings, and welcome to the Avadel Pharmaceuticals Third Quarter 2023 Earnings Call. [Operator Instructions].
Source: insidermonkey.com
Avadel Pharmaceuticals ADRs Rise 19% on 3Q Revenue Growth of Lumryz Sales
By Denny Jacob American depositary receipts of Avadel Pharmaceuticals rose 19% to $12.34 on revenue growth powered by sales of Lumryz in the third quarter....
Source: marketwatch.com